MyoKardia是一家处于临床阶段的生物医药公司,致力于发现和开发针对严重心血管疾病的靶向疗法。通过本次收购,百时美施贵宝...查看全文
空之客2020-10-06 00:12
$百时美施贵宝(BMY)$ 花$13.1bn cash收购$Myokardia(MYOK)$ ,获得一个治疗阻塞性肥厚心肌病HCM的FIC药物、预计明年Q1交NDA,外带俩还在临床的药物。
要不是巨头出手,我都快忘了之前还看过这个疾病方向,以及这家专注做针对心肌蛋白质的小分子药的公司。
讲道理公司是个好公司,可是这价...查看全文
每天一飞刀2020-10-05 22:57
$Myokardia(MYOK)$ Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion in Cash
网页链接查看全文
chuminhua2020-09-01 13:58
8/29,ESC:一项关键III期Explorer-HCM研究结果显示,MyoKardia$Myokardia(MYOK)$ 的mavacamten可通过防止与疾病相关的增厚的心肌阻塞血液流动,从而作为专门针对肥厚型心肌病(HCM)的疗法。结果显示,每天一次给予药物,在30周后显示出心脏功能和耗氧量的统计学显着改善,接受治疗的患者中有36.6...查看全文
chuminhua2020-07-24 15:33
7/23, MyoKardia公司$Myokardia(MYOK)$ 今天宣布,美国食品药品监督管理局(FDA)已授予该公司开发的mavacamten突破性疗法认定,用于治疗症状性、梗阻性肥厚型心肌病(HCM)。Mavacamten是一种新型、口服心肌肌球蛋白变构调节剂。查看全文
牛唐2020-05-12 21:27
桑德斯退选,疫情催化,ASCO当前,生物医药看来是要屡创新高了$美国生科ETF-SPDR(XBI)$ $Protagonist(PTGX)$ $Myokardia(MYOK)$查看全文
chuminhua2020-05-12 11:53
5/11,MyoKardia公司$Myokardia(MYOK)$ 宣布,其在研新药mavacamten在治疗症状性、肥厚性梗阻型心肌病(symptomatic, obstructive hypertrophic cardiomyopathy,HCM)患者的关键性3期临床研究EXPLORER-HCM中,达到该试验的主要终点和所有次要终点。与安慰剂组相比,mavacamten的治疗使患者实现了...查看全文
$Myokardia(MYOK)$ 15-12B Securities registration termination [Section 12(b)] Accession Number: 0001140361-20-026715 Act: 34 Size: 10 KB 网页链接
$Myokardia(MYOK)$ SC 13G Statement of acquisition of beneficial ownership by individuals Accession Number: 0001319244-20-000178 Act: 34 Size: 139 KB 网页链接
$Myokardia(MYOK)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-20-302575 Act: 33 Size: 24 KB 网页链接
$Myokardia(MYOK)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-20-302569 Act: 33 Size: 24 KB 网页链接
$Myokardia(MYOK)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-20-302585 Act: 33 Size: 24 KB 网页链接
$Myokardia(MYOK)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-20-302579 Act: 33 Size: 24 KB 网页链接
$Myokardia(MYOK)$ S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments Accession Number: 0001193125-20-302589 Act: 33 Size: 24 KB 网页链接
$Myokardia(MYOK)$ POSASR Post-effective Amendment to an automatic shelf registration statement Accession Number: 0001193125-20-302559 Act: 33 Size: 17 KB 网页链接
$Myokardia(MYOK)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-031762 Size: 30 KB 网页链接
$Myokardia(MYOK)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000899243-20-031763 Size: 22 KB 网页链接